AZD9898
Modify Date: 2025-08-27 17:03:43
AZD9898 structure
|
Common Name | AZD9898 | ||
|---|---|---|---|---|
| CAS Number | 2042347-69-1 | Molecular Weight | 457.83 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H19ClF3N3O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AZD9898AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 mitigates the GABA binding and hepatic toxicity signal. AZD9898 has the potential to treat asthma[1]. |
| Name | AZD9898 |
|---|
| Description | AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 mitigates the GABA binding and hepatic toxicity signal. AZD9898 has the potential to treat asthma[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.28 nM (LTC4S)[1]. |
| In Vivo | AZD9898 with the single dose of 100 mg/kg is well tolerated and no safety concerns are raised[1]. Animal Model: Rat 6M/group[1]. Dosage: 10 and 100 mg/kg (for Toxicology Study). Administration: Sing oral dose. Result: Showed no signs of testicular toxicity, and only adaptive changes in the liver due to cytochrome P450 induction which were not judged adverse, providing a 200 fold margin between the no adverse effect level and the predicted human exposure at the predicted therapeutic dose. |
| References |
| Molecular Formula | C20H19ClF3N3O4 |
|---|---|
| Molecular Weight | 457.83 |